Author

Jose L. Rivas

Observed names: J.L. Rivas, Jose L Rivas, Jose Luis Rivas, Jose Rivas, Rivas JL, Rivas, Jose L, Rivas, Jose L.

Observed institutions: University of North Carolina at Chapel Hill, Brigham and Women's Hospital, Mayo Clinic, University of Miami, Hospital Universitari i Politècnic La Fe, Metroplex Clinical Research Center, Pfizer (Spain), Miami Transplant Institute, AbbVie (Spain), University of Nebraska Medical Center, The University of Texas Southwestern Medical Center

ORCID: 0009-0004-6736-3962

Observed ORCID: 0009-0004-6736-3962

OpenAlex ID: A5030754645

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

2022 · Steven R. Ytterberg, Deepak L. Bhatt, et al. · New England Journal of Medicine · 1,836

PDF

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

2022 · Christina Charles-Schoeman, Maya H Buch, et al. · Annals of the Rheumatic Diseases · 223

PDF

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry

2021 · Joel M. Kremer, Clifton O. Bingham, et al. · ACR Open Rheumatology · 145

PDF

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

2023 · Lars Erik Kristensen, Silvio Danese, et al. · Annals of the Rheumatic Diseases · 129

PDF

Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

2018 · Jose Luis Rivas, Teresa Palencia, et al. · Frontiers in Immunology · 70

PDF

Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial

2019 · Stanley B Cohen, Janet Pope, et al. · The Lancet Rheumatology · 38

Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant

2014 · Jeffrey J. Gaynor, Gaetano Ciancio, et al. · Diabetologia · 33

Multivariable risk of developing new onset diabetes after transplant—results from a single‐center study of 481 adult, primary kidney transplant recipients

2015 · Jeffrey J. Gaynor, Gaetano Ciancio, et al. · Clinical Transplantation · 27

Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

2023 · Maxime Dougados, Christina Charles-Schoeman, et al. · Annals of the Rheumatic Diseases · 19

PDF

Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment

2021 · Kevin L. Winthrop, Jeffrey R. Curtis, et al. · Rheumatology and Therapy · 18

PDF

Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis

2020 · Stanley B. Cohen, Jeffrey D. Greenberg, et al. · Advances in Therapy · 14

PDF

A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis

2017 · The ECO-DAI Group, Eugenio de Miguel, et al. · Rheumatology International · 13

Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease

2025 · Jon T. Giles, Christina Charles-Schoeman, et al. · Annals of the Rheumatic Diseases · 7

Use of Tofacitinib in the Context of COVID‐19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases

2021 · Mahta Mortezavi, Sujatha Menon, et al. · Arthritis & Rheumatology · 6

PDF

Analysis of the Impact of Tofacitinib Treatment on Weight and Body Mass Index in Patients With Rheumatoid Arthritis

2025 · Jürgen Wollenhaupt, Jacques Morel, et al. · ACR Open Rheumatology · 4

PDF

Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance

2024 · Bogdan Batko, Slawomir Jeka, et al. · Rheumatology and Therapy · 4

Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors

2024 · Gustavo Citera, Eduardo Mysler, et al. · JCR Journal of Clinical Rheumatology · 4

Pos0674 Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥50 Years With Rheumatoid Arthritis and ≥1 Additional Cardiovascular Risk Factor: a Post Hoc Analysis of Oral Surveillance

2022 · C. Charles-Schoeman, M.H. Buch, et al. · Annals of the Rheumatic Diseases · 4

PDF

Lb0004 Methotrexate Withdrawal in Patients With Rheumatoid Arthritis Who Achieve Low Disease Activity With Tofacitinib Modified-release 11 Mg Once Daily + Methotrexate: a Randomised Non-inferiority Phase 3b/4 Study

2019 · Stanley B. Cohen, Janet Pope, et al. · Annals of the Rheumatic Diseases · 3

PDF

Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention

2024 · Janet Pope, Axel Finckh, et al. · Open Access Rheumatology Research and Reviews · 2

PDF

Ab0449 Pain Reduction in Patients With Rheumatoid Arthritis Receiving Tofacitinib Monotherapy With or Without Pain Medication: a Post Hoc Analysis of Pooled Data From Phase 2, Phase 3 and Phase 3b/4 Studies

2019 · Peter C. Taylor, Mart van de Laar, et al. · Annals of the Rheumatic Diseases · 2

PDF

FRI0586 Doppler Ultrasound Better Predicts X-Ray Progression in Rheumatoid Arthritis than Any Definition of Clinical Remission

2015 · E. de Miguel, E. de Vicente, et al. · Annals of the Rheumatic Diseases · 2

POS0651 CLINICAL AND FUNCTIONAL RESPONSE TO TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: PROBABILITY PLOT ANALYSIS OF RESULTS FROM A 48-WEEK PHASE 3b/4 METHOTREXATE WITHDRAWAL STUDY

2021 · S.B. Cohen, Y.H. Chen, et al. · Annals of the Rheumatic Diseases · 1

Ab0454 Frequency and Duration of Early Non-serious Adverse Events in Rheumatoid Arthritis Patients Treated With Tofacitinib 5 Mg Twice Daily as Monotherapy and Combination Therapy

2019 · Ara Dikranian, Jürgen Wollenhaupt, et al. · Annals of the Rheumatic Diseases · 1

PDF

Ab0417 Efficacy and Safety of Tofacitinib in Patients With Rheumatoid Arthritis According to Duration of Prior Csdmard Treatment and Number of Prior Csdmards: a Post Hoc Analysis of Phase 3 and Phase 3b/4 Trials

2019 · Daniel Aletaha, Juan Jose Gomez-Reino, et al. · Annals of the Rheumatic Diseases · 1

PDF

Works count: 44

Citation count: 2,607

H-index: 12

I10-index: 12